Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the
treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it …

With the availability of a therapeutic target and an effective agent in trastuzumab, a
systematic examination of the literature to investigate the role of human epidermal growth …

Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is
implicated in the development of various solid tumour types. Validated methods and scoring …

Amplification of the HER2 gene and over-expression of the HER2 protein in gastric cancer
have been shown in a large number of studies. HER2 positivity can be detected in …

Advances in molecular methods have massively facilitated the discovery of potential
molecular targets for gene-specific therapy. Accelerated lead discovery has at the same time …

Gastric cancer (GC) is a major public health issue as the fourth most common cancer and
the second leading cause of cancer-related death. Recent advances have improved our …

Recent evidence suggests that trastuzumab, a monoclonal antibody which targets HER2, in
combination with chemotherapy is a therapeutic option in patients with HER2-positive …

Gastric cancer is one of the leading causes of cancer-related deaths worldwide, although
the incidence has gradually decreased in many Western countries. Two main gastric cancer …

Gastric cancer has an important place in the worldwide incidence of cancer and cancer-
related deaths. It can metastasize to the lymph nodes in the early stages, and lymph node …

Background HER2 has a predictive value in gastric cancer. However, its association with
prognosis remains uncertain. The aim of our study was to estimate the HER2-positive rate in …